Clinical observation of montelukast in prevention of Henoch-Schonlein purpura with renal impairment

Abstract

Abstract: AIM: To observe the clinical efficacy and safety of montelukast in prevention of Henoch-Schonlein purpura with renal impairment. METHODS: Using a randomized controlled method, 200 cases of Henoch-Schonlein syndrome were randomly divided into the experimental group (n=100)and control group (n=100),two groups were given conventional treatment,the experimental group was based on combined with montelukast and the control group was based on combined with low molecular heparin sodium.The clinical treatment result,the changes of urine albumin and β₂ microglobulin levels in different time periods were observed.RESULTS:Efficacy of the experimental group was 91.00% while the control group was 81.00% (χ²=4.15, P<0.05) .Compared with the control group,the children disappearing time rash, abdominal pain and joint pain remission time and the total duration in the experimental group were significantly shorter (P<0.01). After treatment, the levels of urinary albumin and urinary β₂ microglobulin in experimental group were significantly lower than those in the control group (P<0.01). CONCLUSION: The preventive effect of montelukast on henoch-schonlein purpura with renal involvement method is simple,safe,so it deserves preference in clinic.

Key words: montelukast, henoch-schonlein purpura, henoch-schonlein purpura nephritis

CLC Number:

R729

CHEN Su-zhe, ZHOU Yao-lin. Clinical observation of montelukast in prevention of Henoch-Schonlein purpura with renal impairment[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(7): 805-808.

References

[1] Ru L, Abudouhaer A, Guo YF.Clinical significance of serum levels of IGF-1 and IGFBP-3 in children with Henoch-Schonlein purpura or Henoch-Schonlein purpura nephritis[J] .Zhongguo Dang Dai Er Ke Za Zhi,2013,15(11):1009-1013.
[2] Huang D, Wu X, Zheng W, et al.Podocalyxin expression in renal tissues and correlation with the number of urinary podocytes in children with Henoch-Schonlein purpura nephritis[J].Zhong Nan Da Xue Xue Bao Yi Xue Ban,2012,37(2):161-167.
[3] 中华医学会儿科学分会肾脏病学组.紫癜性肾炎的诊断与治疗(草案)[J].中国实用儿科杂志,2003,18:189.
[4] 胡晓燕. 孟鲁司特钠治疗儿童过敏性紫曩临床分析[J].实用医学杂志,2011,27(12):2235-2236.
[5] De Almeida JL, Campos LM, Paim LB,et al.Renal involvementin Henoch-Schonlein purpura: a multivariate analysis of initialprognostic factors[J].J Pediatr (RioJ), 2007, 83(3):259-266.
[6] 方湘玲,易着文,党西强,等.儿童过敏性紫癜 236 例临床分析[J].临床儿科杂 2006, 24(1):46-49.
[7] Borawski J, Naumnik B, Pawlak K, et al.Soluble thrombomodulin is associated with viral hepatitis, blood pressure, and medications in haemodialysis patients[J]. Nephrol Dial Transplant,2001,16(4):787-792.
[8] Huber AM, King J, McLaine P, et al. A randomized, placebo-controllde trial of prednisone in early Henoch-Schonlein purpura[J]. BMC Med, 2004,2(1):7.
[9] 廖培元,吴升华.过敏性紫癜患儿血清白三烯B4、白介素5的测定及临床意义[J].中国当代儿科杂志,2006,8(3):198-200.
[10] 马陆,郭晓渊,皮文霞.孟鲁司特钠治疗婴幼儿非特应性喘息症的疗效分析[J]. 中国临床药理学与治疗学,2011,16(11): 1300-1303.
[11] 李建新,申军.孟鲁司特治疗过敏性紫癜的疗效分析[J].临床与实验医学杂志,2010,9(10) : 61-62.
[12] 王秀萍,曹雪梅,李锋同.孟鲁司特钠治疗过敏性紫癜36例[J].陕西医学杂志,2012,41(5) : 599-601.
[13] 郁颖伶. 孟鲁司特治疗过敏性紫癜 30例临床分析[J].南通大学学报: 医学版,2010,30(6) : 465-466.
[14] 鲁迎. 孟鲁司特治疗过敏性紫癜临床观察[J].临床合理用药,2012,5(1) : 61-62.
[15] Reinhold SW,vitzthum H,Filbeck T,et al.Gene expression of 5-, 12-, and 15-lipoxygenases andleukotriene receptors along the rat nephron[J].Am J Physiol Renal Physiol,2006,290(4):864-872.
[16] Kurogi Y.Mesangial cell proliferation inhibitors for the treatmentof proliferative glomerular disease[J].Med Res Rev,2003,23(1):15-31.